ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

2018 American Transplant Congress » Concurrent Session: Kidney Chronic Antibody Mediated Rejection

Date: Monday, June 4, 2018

Time: 2:30pm-4:00pm

Location: Room 4B

Session Type: Concurrent Session

Meeting: 2018 American Transplant Congress

2:30pm-2:42pm
Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection – A Double-Blind Randomized Placebo-Controlled Trial (BORTEJECT Study)

F. Eskandary,1 H. Regele,2 G. Bond,1 N. Kozakowski,2 M. Wahrmann,1 L. Hidalgo,3 H. Haslacher,4 C. Kaltenecker,1 M-.B. Aretin,5 R. Oberbauer,1 J. Reeve,6 P. Halloran,6 G. Böhmig.1

2:42pm-2:54pm
Tocilizumab Stabilizes Renal Function in Kidney Transplant Recipients with Chronic Active Antibody Mediated Rejection (CAAMR)

S. Patel, S. Mohan, H. Fernandez, I. Batal, L. Ratner, J. Crew.

2:54pm-3:06pm
Extended Experience Using Tocilizumab (Anti-IL6R, TCZ) for the Treatment of Chronic Antibody Mediated Rejection (CABMR)

J. Choi,1 O. Aubert,2 S. Louie,1 N. Ammerman,1 A. Vo,1 A. Peng,1 E. Huang,1 R. Najjar,1 D. Puliyanda,1 S. Sethi,1 M. Haas,1 K. Lim,1 A. Loupy,2 S. Jordan.1

3:06pm-3:18pm
Class II Anti-HLA IgG2 and IgG3 DSAs Predict Poorer Outcomes in Chronic Antibody Mediated Rejection of Renal Allografts

A. Gueret-Wardle,1 G. Lucisano,1 S. Hassan,1 P. Brookes,2 E. Santos-Nunez,2 D. Goodall,1 C. Clarke,1 J. Galliford,1 M. Willicombe,1 D. Taube.1

3:18pm-3:30pm
Antibody-Verified Eplet Mismatches as Determinants of Premature Kidney Transplant Loss

R. Sapir-Pichhadze,1 X. Zhang,1 A. Ferradji,1 A. Madbouly,2 S. Fingerson,2 K. Tinckam,5 H. Gebel,3 H. Cardinal,4 B. Foster.1

3:30pm-3:42pm
Treatment of Active Chronic Antibody-Mediated Rejection with Rituximab, IVIG and Plasma Exchange

G. Piñeiro,1 J. Rovira,2 E. De Sousa-Amorim,1 J. Villarreal,1 M. Sole,3 I. Revuelta,1 M. Lozano,4 E. Palou,4 F. Oppenheimer,1 J. Campistol,1 F. Diekmann.1,2

3:42pm-3:54pm
Inflammation in Scarred Areas (I-IFTA) is a Reflection of Parenchymal Injury (Response to Wounding) Not T Cell-Mediated Rejection

P. Halloran, J. Chang, K. Famulski.

« View all sessions from the 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences